Empagliflozin/metformin - Boehringer Ingelheim/Eli Lilly and Company
Alternative Names: BI-10773/metformin; Empagliflozin/metformin extended-release; Empagliflozin/metformin immediate-release; Gibtulio Met; Metformin/BI-10773; Metformin/empagliflozin; Metformin/empagliflozin extended-release; Metformin/empagliflozin immediate-release; Metformin/empagliflozin XR; Oboravo Met; Synjardy; Synjardy XRLatest Information Update: 30 Jun 2023
Price :
$50 *
At a glance
- Originator Boehringer Ingelheim
- Developer Boehringer Ingelheim; Eli Lilly and Company
- Class Antihyperglycaemics; Benzhydryl compounds; Biguanides; Cyclic ethers; Glucosides; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Type 2 diabetes mellitus
Most Recent Events
- 22 Jun 2023 Registered for Type 2 diabetes mellitus (In adolescents, In children) in USA (PO)
- 20 Jun 2023 Efficacy data from a phase III trial in Type-2 diabetes mellitus released by Boehringer Ingelheim
- 09 Sep 2021 Boehringer Ingelheim completes a phase I bioavailability trial (In volunteers) in Brazil (NCT05083949)